Anti-tumor necrosis factor therapies are still suspected of contributing to malignancy development, though it remains unproven. A 53-year-old female patient was admitted to our clinic with the complaints of fatigue, weight loss and rectal bleeding. She suffered from ankylosing spondylitis and had been treated with infliximab. Colonoscopic examination showed bleeding and ulcerated polypoid tumor in the cecum. Pathological examination of the material revealed adenocarcinoma. We discuss the high probability of a serious adverse effect of infliximab as an anti-tumor necrosis factor agent.
Alan : Sağlık Bilimleri
Dergi Türü : Uluslararası
Benzer Makaleler | Yazar | # |
---|
Makale | Yazar | # |
---|